Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | GRM5 | P41594 | 8/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | GBA1 | P04062 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31151002 | 1.00 | RAB9A (0.62) | RAB9AGRM5KMT2AMEN1GBA1 | |
| SCHEMBL29394473 | 0.90 | LCK (0.47) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL5093445 | 0.84 | RAB9A (0.52) | RAB9AGRM5KMT2AMEN1GBA1 | |
| SCHEMBL29510654 | 0.84 | ALDH1A1 (0.51) | GRM5KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL22523913 | 0.84 | LCK (0.43) | RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL1712579 | 0.84 | ALDH1A1 (0.51) | GRM5KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL14622117 | 0.84 | LCK (0.43) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL12710236 | 0.83 | LCK (0.42) | RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL31009974 | 0.83 | LCK (0.42) | RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL29340731 | 0.83 | LCK (0.42) | RAB9AKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546235-B1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | NIPPON SODA CO (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2488513-B1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC IMMUNE SA (CH) | 2017-12-27 | — | — | EP | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2842944-B1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | NIPPON SODA CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2557078-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND METHOD FOR PRODUCING SAME | NIPPON SODA CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| EP-2730561-B1 | Methods to prepare haloalkyl nitrogen-containing heterocyclic compounds | NIPPON SODA CO (JP) | 2015-10-14 | — | — | EP | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0880511-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0880511-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998030542-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997026250-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0099770-B1 | OXAZINOBENZOTHIAZINE-6,6-DIOXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENT | PROVESAN S.A. (CH) | 1986-08-27 | — | — | EP | disclosed |
| US-4563452-A | ANTIINFLAMMATORY, ANALGESIC | PROVESAN S.A. (CH) | 1986-01-07 | — | — | US | disclosed |
| EP-0099770-A1 | Oxazinobenzothiazine-6,6-dioxide derivatives, their preparation and their use as medicament | PROVESAN S.A. (CH) | 1984-02-01 | — | — | EP | disclosed |